Evidence map›Paper›PMID 31830115›Full record

ArticlePloS one2019

Long-term outcome in patients after treatment for Cushing's disease in childhood.

Katarzyna Pasternak-Pietrzak, Elżbieta Moszczyńska, Marcin Roszkowski, Karolina Kot, Elżbieta Marczak, Wiesława Grajkowska, Maciej Pronicki, Mieczysław Szalecki

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Cushing disease in pediatrics: an update.Annals of pediatric endocrinology & metabolism · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Katarzyna Pasternak-PietrzakDepartment of Endocrinology and Diabetology, The Children's Memorial Health Institute (CMHI), Warsaw, Poland.ORCID 0000-0001-9602-5023
Elżbieta MoszczyńskaDepartment of Endocrinology and Diabetology, The Children's Memorial Health Institute (CMHI), Warsaw, Poland.
Marcin RoszkowskiDepartment of Neurosurgery, The Children's Memorial Health Institute (CMHI), Warsaw, Poland.
Karolina KotDepartment of Endocrinology and Diabetology, The Children's Memorial Health Institute (CMHI), Warsaw, Poland.
Elżbieta MarczakDepartment of Endocrinology and Diabetology, The Children's Memorial Health Institute (CMHI), Warsaw, Poland.
Wiesława GrajkowskaPathology Department, The Children's Memorial Health Institute, Warsaw, Poland.
Maciej PronickiPathology Department, The Children's Memorial Health Institute, Warsaw, Poland.
Mieczysław SzaleckiDepartment of Endocrinology and Diabetology, The Children's Memorial Health Institute (CMHI), Warsaw, Poland.
Children's Memorial Health Institute · PLJan Kochanowski University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCushing's disease (CD) is a rare cause of hypercortisolemia presenting a major diagnostic and therapeutic challenge. Data on pituitary function in long-term follow-up after CD treatment in childhood is limited.

aimLong-term assessment of patients of the Children's Memorial Health Institute (CMHI) after CD treatment in childhood. MATERIALS AND

methodsRetrospective analysis of 29 CD patients, mean age at the time of diagnosis 13.46 yrs. The long-term follow-up (FU) was done by: 1) obtaining the data from a patient's questionnaire (75% of adult patients); 2) using the data from the last clinic visit for patients who did not respond to the questionnaire and for current CMHI patients. The average long-term FU from transsphenoidal pituitary surgery (TSS) was 10.23 yrs.

resultsAt the latest FU: 18 patients (62%) had long-term disease remission after TSS1, 2 patients (6.9%) after TSS2, 1 patient (3.4%) after the post-TSS radiotherapy (XRT) cycle and 3 patients (10.3%) after bilateral adrenalectomy (BA). One patient (3.4%) died after TSS2 due to postoperative complications, 1 patient (3.4%) had persistent disease at latest FU, in 1 patient (3.4%) the long-term FU was not possible to perform. CD recurrence occurred in 4 out of 28 patients (14%) at an average time 3.6 yrs. from definitive treatment. One patient (3.4%) after BA was operated because of Nelson's syndrome. Two patients (6.9%) were suspected of relapse at latest assessment. At the time of the last evaluation, 17 patients (63%) were on levothyroxine therapy since definitive treatment, 16 patients (59%) were on hydrocortisone treatment, 10 patients (37%) were taking sex hormones replacement, 4 patients (15%)-antidiuretic hormone.

conclusionsRelatively large number of patients after CD treatment in childhood have hormonal pituitary deficits as well as mood and cognitive disorders. CD recurrence can occur even after a long time post effective treatment.

Indexed as

AdenomaAdolescentAdultAge of OnsetChildChild DevelopmentChild, PreschoolFemaleFollow-Up StudiesHumansMaleNeoplasm Recurrence, LocalPituitary ACTH HypersecretionPituitary Function TestsPituitary NeoplasmsPoland

Identifiers

PMID31830115
PMCPMC6907843
OpenAlexW2994689891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.